Lactitol properties in the treatment of patients with lifestyle-related diseases

M. Maevskaya, S. V. Okovityi
{"title":"Lactitol properties in the treatment of patients with lifestyle-related diseases","authors":"M. Maevskaya, S. V. Okovityi","doi":"10.21518/ms2024-184","DOIUrl":null,"url":null,"abstract":"Russia and most countries of the world are currently facing pressures on their health services because of the growing number of diseases associated with unhealthy lifestyles: type 2 diabetes, obesity, non-alcoholic fatty liver disease, etc. Lifestyle modification is the first prerequisite in the treatment of non-alcoholic fatty liver disease and other diseases associated with unhealthy lifestyle. The use of lactitol provides the opportunity to make this process more effective, as it is able to increase the production of butyrate, reduce the damage to the intestine barrier structure, and interact with sweet-taste receptors. Lactitol has a low glycaemic index, it is not absorbed in the intestine and is fermented like dietary fibres. The results of the studies showed that the metabolic response to this drug corresponds to a lower increase in plasma glucose, insulin and C-peptide levels compared to the use of glucose in healthy, non-obese men. It has been shown through various experiments in animals and in humans that lactitol also reduces the plasma triglyceride levels, probably due to reduced triglyceride absorption as a result of accelerated transit of intestinal contents. An important property of the drug is its ability to increase the glucagon-like peptide-1 (GLP-1) and PYY levels, which is accompanied by delayed gastric emptying and reduced hunger, which is essential in the treatment of obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease. A 120-day randomized controlled trial was conducted to assess the efficacy, safety, and tolerability of lactitol in 139 patients with nonalcoholic fatty liver disease. Twice-daily administration of lactitol 6 g in addition to lifestyle modification events has been shown to increase their efficacy expressed as a significant decrease in ALT levels and an increase in the AST/ALT ratio compared to control subjects. Lactitol can be considered as a metabolic corrector and used in the treatment of diseases associated with an unhealthy lifestyle.","PeriodicalId":18391,"journal":{"name":"Meditsinskiy sovet = Medical Council","volume":"109 47","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Meditsinskiy sovet = Medical Council","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21518/ms2024-184","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Russia and most countries of the world are currently facing pressures on their health services because of the growing number of diseases associated with unhealthy lifestyles: type 2 diabetes, obesity, non-alcoholic fatty liver disease, etc. Lifestyle modification is the first prerequisite in the treatment of non-alcoholic fatty liver disease and other diseases associated with unhealthy lifestyle. The use of lactitol provides the opportunity to make this process more effective, as it is able to increase the production of butyrate, reduce the damage to the intestine barrier structure, and interact with sweet-taste receptors. Lactitol has a low glycaemic index, it is not absorbed in the intestine and is fermented like dietary fibres. The results of the studies showed that the metabolic response to this drug corresponds to a lower increase in plasma glucose, insulin and C-peptide levels compared to the use of glucose in healthy, non-obese men. It has been shown through various experiments in animals and in humans that lactitol also reduces the plasma triglyceride levels, probably due to reduced triglyceride absorption as a result of accelerated transit of intestinal contents. An important property of the drug is its ability to increase the glucagon-like peptide-1 (GLP-1) and PYY levels, which is accompanied by delayed gastric emptying and reduced hunger, which is essential in the treatment of obesity, type 2 diabetes mellitus and non-alcoholic fatty liver disease. A 120-day randomized controlled trial was conducted to assess the efficacy, safety, and tolerability of lactitol in 139 patients with nonalcoholic fatty liver disease. Twice-daily administration of lactitol 6 g in addition to lifestyle modification events has been shown to increase their efficacy expressed as a significant decrease in ALT levels and an increase in the AST/ALT ratio compared to control subjects. Lactitol can be considered as a metabolic corrector and used in the treatment of diseases associated with an unhealthy lifestyle.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳糖醇在治疗生活方式相关疾病患者中的作用
俄罗斯和世界上大多数国家目前都面临着医疗服务的压力,因为与不健康生活方式相关的疾病日益增多:2 型糖尿病、肥胖症、非酒精性脂肪肝等。改变生活方式是治疗非酒精性脂肪肝和其他与不健康生活方式相关疾病的首要前提。乳糖醇能够增加丁酸盐的产生,减少对肠道屏障结构的破坏,并与甜味受体相互作用,因此乳糖醇的使用为提高这一过程的有效性提供了机会。乳糖醇的血糖指数较低,不会被肠道吸收,而且会像膳食纤维一样被发酵。研究结果表明,与使用葡萄糖相比,健康、非肥胖男性对这种药物的代谢反应相当于较低的血浆葡萄糖、胰岛素和 C 肽水平的增加。各种动物和人体实验表明,乳糖醇还能降低血浆中甘油三酯的水平,这可能是由于肠道内容物加速转运,减少了甘油三酯的吸收。该药物的一个重要特性是能够提高胰高血糖素样肽-1(GLP-1)和PYY的水平,从而延迟胃排空,减少饥饿感,这对治疗肥胖症、2 型糖尿病和非酒精性脂肪肝至关重要。一项为期 120 天的随机对照试验评估了乳糖醇对 139 名非酒精性脂肪肝患者的疗效、安全性和耐受性。结果表明,与对照组相比,每天两次服用乳糖醇(6 克)以及改变生活方式可提高疗效,具体表现为谷丙转氨酶(ALT)水平显著下降,谷草转氨酶(AST)/谷丙转氨酶(ALT)比值上升。乳糖醇可被视为一种代谢调节剂,用于治疗与不健康生活方式有关的疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Clinical and pathogenetic features of thyropathies diagnosed during the post-COVID-19 period Lung cancer associated with an activating mutation in the 14th exon of the MET gene Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety Experience with the use of nivolumab and ipilimumab in metastatic fibrolamellar liver carcinoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1